Twist Bioscience (NASDAQ:TWST) Reaches New 12-Month High – What’s Next?

Twist Bioscience Corporation (NASDAQ:TWST)’s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $51.83 and last traded at $51.1350, with a volume of 619747 shares trading hands. The stock had previously closed at $49.11.

Analyst Ratings Changes

TWST has been the topic of several recent analyst reports. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a report on Tuesday, February 3rd. Stephens assumed coverage on Twist Bioscience in a research note on Monday, November 3rd. They set an “overweight” rating and a $41.00 target price for the company. Finally, Barclays boosted their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $45.88.

Twist Bioscience Stock Down 4.4%

The business has a 50-day moving average price of $40.24 and a 200-day moving average price of $32.99. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -41.01 and a beta of 2.24. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. The business’s revenue was up 16.9% on a year-over-year basis. As a group, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, SVP Paula Green sold 1,194 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total transaction of $55,616.52. Following the transaction, the senior vice president owned 165,445 shares in the company, valued at approximately $7,706,428.10. This trade represents a 0.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jan Johannessen sold 2,200 shares of Twist Bioscience stock in a transaction on Friday, February 6th. The shares were sold at an average price of $47.91, for a total transaction of $105,402.00. Following the completion of the sale, the director directly owned 17,754 shares of the company’s stock, valued at approximately $850,594.14. The trade was a 11.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 36,609 shares of company stock worth $1,665,151. 3.08% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC increased its holdings in Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after buying an additional 832,687 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Twist Bioscience by 26.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after acquiring an additional 1,349,867 shares in the last quarter. William Blair Investment Management LLC increased its stake in Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after acquiring an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. raised its position in Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after purchasing an additional 1,295,672 shares in the last quarter. Finally, State Street Corp raised its position in Twist Bioscience by 17.4% in the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after purchasing an additional 538,755 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.